Skip to content

Silicone vs Pirfenidone in the Treatment of Hypertrophic Scars and Keloids

A Observer Blind Randomized Controlled Pilot Trial to Determine the Equivalence of a Silicone Gel With Superoxidized Water vs. a Pirfenidone Gel for the Treatment of Hypertrophic Scars and Keloids

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06909812
Enrollment
40
Registered
2025-04-04
Start date
2015-07-14
Completion date
2016-01-20
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Scar, Keloids, Scars

Keywords

scars, keloids, hyperthrophic, pirfenidone

Brief summary

Justification: Keloid scars are a major medical and cosmetic problem, especially in darker skin types that predominate in Mexico. It is estimated that hypertrophic scars affecting from 1.5 to 4.5% of the general population. However, the exact prevalence is unknown but studies show that going from 32 to 67%. And there are studies documenting that this prevalence is higher in Hispanic and black individuals and in the pediatric population. Keloid scars can become highly symptomatic disfiguring and which affects the quality of life of patients and their self-esteem.Problem Statement: Is silicone gel solutions superoxidation with equal or better than the gel 8% pirfenidone to treat keloids and hypertrophic scars? Goal: To evaluate the efficacy of a silicone gel-oxidation with solutions compared to a gel containing 8% pirfenidone. Hypothesis: If the silicone gel solutions superoxidation is equal or better than gel 8% pirfenidone to treat keloids and hypertrophic scars, then the reduction in the ECV and the EVA will be similar in the first group than the second. Design: Comparative, observer blind, experimental and prospective study.

Detailed description

This is a comparative, non-inferiority, experimental, prospective, longitudinal pilot study with blind evaluator, in patients with keloid or hypertrophic scars. Twenty patients per group randomly assigned to receive identical tubes of either a silicone-based gel with superoxidized water, or an 8% pirfenidone gel. Follow-up was scheduled at 2, 4, 8, 12, and 16 weeks recording the location, mechanism of the scar, time of evolution, skin phototype, accompanying symptoms, Dermatology Life Quality Index, and validated scar assessment tools (Patient and Observer Scar Assessment Scale, Vancouver Scar Scale, and the Analog Visual Scale for Keloids).

Interventions

DRUGpirfenidone 8% gel

topic aplication

DRUGsilicon gel

topic aplication

Sponsors

Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Tubes containg both active treatments were identical. Outcomes assessor was blinded to treatment arm.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* keloid or hypetrophic scar

Exclusion criteria

* collagen diseases pregnancy previous treatment for 3 months

Design outcomes

Primary

MeasureTime frameDescription
Dermatology Life Quality Index Score3 monthsA life quality index for dermatological conditions
Patient and Observer Scar Assessment Scale Score3 monthsA validated scale (POSAS and OSAS) to assess relevant clinical characteristics of scars.
Vancouver Scar Scale3 monthsA validated scar scale

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026